BRAF突变结直肠癌:预后、治疗与新视角
本文综述BRAF突变转移性结直肠癌(mCRC)的临床与分子特征,指出该突变与不良预后相关且抗EGFR抗体获益较少;单药BRAF抑制剂在mCRC疗效差,已发现多种耐药机制,合理联合靶向治疗有望提高选择性BRAF抑制剂疗效,并讨论下一代测序与基因表达分型等未来方向。
要点
- BRAF突变与mCRC不良预后相关,且抗EGFR抗体治疗获益较少。
- 单药BRAF抑制剂在mCRC疗效差,不同于BRAF突变黑色素瘤。
- 已发现多种耐药机制,合理联合靶向治疗在早期试验显示有前景的活性。
核心结论
- BRAF突变mCRC预后差且抗EGFR抗体获益较少,单药BRAF抑制剂疗效差,合理联合靶向治疗有望提高选择性BRAF抑制剂疗效。
研究设计与样本
- 综述,讨论BRAF突变结直肠癌的主要临床与分子特征及其临床转化,重点为开发性治疗与联合策略。
主要发现
- MAPK级联在肿瘤细胞增殖与存活中起关键作用,BRAF癌基因突变与mCRC不良预后相关。
- BRAF突变mCRC接受抗EGFR抗体治疗时获益较少。
- 与BRAF突变黑色素瘤不同,BRAF抑制剂单药在mCRC中疗效差。
- 已发现多种耐药机制,促成不同治疗策略的开发,早期临床试验显示有前景的活性。
- 合理联合靶向治疗预期可进一步提高选择性BRAF抑制剂的疗效。
临床怎么用
- BRAF突变mCRC治疗需考虑联合靶向策略而非单药BRAF抑制剂。
- 可借助下一代测序平台与基因表达策略进行分子分型以识别特定患者特征。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The MAPK cascade plays a crucial role in tumor cell proliferation and survival. Accumulating evidence suggests that mutations in the BRAF oncogene are not only associated with poor prognosis but also linked with less benefit when treated with anti-epidermal growth factor receptor antibodies in metastatic colorectal cancer (mCRC). Targeting this molecular aberration has thus become a matter of particular interest in mCRC drug development. In contrast to other malignances such as BRAF mutant melanoma, efficacy observed with BRAF inhibitors in monotherapy in mCRC is poor. Several mechanisms of resistance have been identified leading to the development of different treatment strategies that have shown promising activity in early clinical trials. Hence, rational combination of targeted therapies is expected to further increase the efficacy of selective BRAF inhibitors. Herein, we discuss the main clinical and molecular characteristics of BRAF mutant colorectal cancer and its translation into the clinic, with a focus on developmental therapeutics and combination strategies. In addition, we contextualize the available data with potential future approaches that include the extended access to next-generation sequencing platforms and gene expression strategies for molecular subtyping. These approaches will facilitate the identification of certain patient profiles providing more therapeutic possibilities.
引用
- Sanz-Garcia E, Argiles G, Elez E, et al. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol. 2017. PMID: 29045527. doi:10.1093/annonc/mdx401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。